Norms of performance of sustained attention among a community sample: Continuous Performance Test study

Abstract  The Continuous Performance Test (CPT) is a widely used measure of sustained attention, which is a preferred tool for assessing various mental functions. A well-established norm for CPT is essential when choosing a suitable threshold for classifying individuals as either case (CPT impairment) or non-case. The CPT performance of 900 adults who were randomly chosen from a community survey was measured to establish the norms for subgroups with different gender, age, and educational levels. The results revealed that age and educational level are significantly associated with the performance sensitivity (d') of CPT. Male subjects perform better than female subjects. Seventeen percent of the subjects scored higher on the masked CPT than on the unmasked CPT. Subjects who could not finish the masked CPT had the characteristics of older age and fewer years of education. When classifying a patient as case or non-case, his/her CPT performance should be considered relative to the norms for his/her gender, age, and educational levels.     

Heterogeneity of memory B cells

Potential solid organ transplant recipients broadly sensitized to HLA have long wait times, low transplant rates and poor outcomes. The new kidney allocation system has improved access to the most highly sensitized recipients; however, their long‐term outcomes are unknown. Emerging data suggest that memory B cell repertoire is broader than the plasma cell repertoire, therefore, despite refinements in anti‐HLA antibody detection technology, donor‐specific HLA‐ specific memory B cells may in fact be present in some, if not most, highly sensitized recipients with no detectable donor‐specific antibodies. In addition, new findings have underscored the heterogeneity in memory B cell generation, and in the signals that determine memory versus plasma cell fate during primary antigen encounter, as well as memory B cell differentiation upon antigen reencounter into plasma cells or reentry into germinal centers to subsequently emerge as higher affinity and class‐switched plasma cells. Thus, heterogeneity memory B cells generation may affect the efficacy of specific immunomodulation during the recall response. We propose that the ability to quantify donor‐specific B cell in transplant recipients is urgently required to provide insights into the mechanisms of sensitization and recall, and for the early detection of acute and chronic AMR.     

The bridge between transplantation and regenerative medicine: Beginning a new Banff classification of tissue engineering pathology

The science of regenerative medicine is arguably older than transplantation—the first major textbook was published in 1901—and a major regenerative medicine meeting took place in 1988, three years before the first Banff transplant pathology meeting. However, the subject of regenerative medicine/tissue engineering pathology has never received focused attention. Defining and classifying tissue engineering pathology is long overdue. In the next decades, the field of transplantation will enlarge at least tenfold, through a hybrid of tissue engineering combined with existing approaches to lessening the organ shortage. Gradually, transplantation pathologists will become tissue‐(re‐) engineering pathologists with enhanced skill sets to address concerns involving the use of bioengineered organs. We outline ways of categorizing abnormalities in tissue‐engineered organs through traditional light microscopy or other modalities including biomarkers. We propose creating a new Banff classification of tissue engineering pathology to standardize and assess de novo bioengineered solid organs transplantable success in vivo. We recommend constructing a framework for a classification of tissue engineering pathology now with interdisciplinary consensus discussions to further develop and finalize the classification at future Banff Transplant Pathology meetings, in collaboration with the human cell atlas project. A possible nosology of pathologic abnormalities in tissue‐engineered organs is suggested.